Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorAlp, E.
dc.contributor.authorYilmaz, A.
dc.contributor.authorÖnen, H.İ.
dc.contributor.authorKonaç, E.
dc.contributor.authorEkmekçi, A.
dc.contributor.authorMenevşe, E.S.
dc.contributor.authorMenevşe, A.
dc.date.accessioned2021-11-01T14:51:42Z
dc.date.available2021-11-01T14:51:42Z
dc.date.issued2020
dc.identifier.issn2147-2092
dc.identifier.urihttps://doi.org/10.12996/gmj.2020.02
dc.identifier.urihttps://hdl.handle.net/11491/6272
dc.description.abstractObjective: Cervical cancer is one of the most tumors seen in womans and second leading cause of cancer death in women. Cisplatin (CDDP), a platin based compound, is the most important chemotherapeutic agent and effectively used for the treatment of sarcomas and solid tumors. It binds to the DNA with crosslinks and leads inhibition of replication, causing DNA damage. As a result of this action, apoptotic pathways are induced and cell death occurs. In our study, we aimed to investigate the effect of CDDP on relative mRNA expression of mTOR, AKT, Cyclin D1 (CCND1) ve STAT3 on cervical cancer cell line. Method: In this study, HeLa cells were treated with different concentrations of CDDP at 24 and 48 hours. Cell viability was determined by XTT method. Moreover, after treatment with selected doses of cisplatin, quantitative mRNA expression of mTOR, AKT, CCND1 and STAT-3 genes was analyzed using Real-Time PCR. Results: IC50 concentration of CDDP was found to be about 60 µM for 24h and 8 µM for 48h treatment. Moreover, all analyzed genes’ expression was shown to diminish only after 24 h treatment. On the other hand, no statistically significant change was found after 48 h cisplatin exposure with respect to quantitative mRNA expression. Conclusion: In summary, different mRNA expression pattern was found after CDDP treatment regarding to exposure time. Our study has been contributed the literature in terms of detecting the effect of conventional chemotherapeutic CDDP on cell survival pathways. © Copyright 2020 by Gazi University Medical Facultyen_US
dc.language.isoturen_US
dc.publisherGazi Universitesien_US
dc.relation.ispartofGazi Medical Journalen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAKTen_US
dc.subjectCCND1en_US
dc.subjectCervical Canceren_US
dc.subjectCisplatinen_US
dc.subjectMRNAen_US
dc.subjectMTORen_US
dc.subjectSTAT3en_US
dc.titleThe effects of cisplatin on mTOR, AKT, CCND1 and STAT3 mRNA expressions on HeLa cellsen_US
dc.typearticleen_US
dc.department[Belirlenecek]en_US
dc.identifier.volume31en_US
dc.identifier.issue1en_US
dc.identifier.startpage5en_US
dc.identifier.endpage9en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-tempAlp, E., Giresun Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji Anabilim Dalı, Giresun, Turkey; Yilmaz, A., Hitit Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji Anabilim Dalı, Corum, 19030, Turkey; Önen, H.İ., Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı, Beşevler, Ankara, 06510, Turkey; Konaç, E., Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı, Beşevler, Ankara, 06510, Turkey; Ekmekçi, A., Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı, Beşevler, Ankara, 06510, Turkey; Menevşe, E.S., Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı, Beşevler, Ankara, 06510, Turkey; Menevşe, A., Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı, Beşevler, Ankara, 06510, Turkeyen_US
dc.contributor.institutionauthor[Belirlenecek]
dc.identifier.doi10.12996/gmj.2020.02
dc.authorscopusid16243955300
dc.authorscopusid57197367725
dc.authorscopusid14054573400
dc.authorscopusid6506305432
dc.authorscopusid36790896000
dc.authorscopusid55378444700
dc.authorscopusid6701872208
dc.description.scopuspublicationid2-s2.0-85078551778en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster